Swiss drugmaker Roche has abandoned global diverse workforce targets and compatriot Novartis is ending its use of diverse ...

Here's why La Roche-Posay is pulling its Effaclar Duo Acne Spot Treatment from retail shelves. La Roche-Posay is a brand under the L'Oreal Group umbrella. A La Roche-Posay spokesperson confirmed ...

Barclays analyst Emily Field maintained a Hold rating on Roche Holding AG (RHHVF – Research Report) today and set a price target of CHF290.00. The company’s shares closed yesterday at $335.00.

LONDON — Looking to expand its obesity offerings, Roche on Wednesday said it had partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion in upfront cash.

The products are being recalled by the FDA for possible "benzene contamination." Acne creams from retailers including Walgreens, La Roche-Posay and Proactiv have been voluntarily recalled due to ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report) and Q32 Bio (QTTB – Research Report). Effectively ...

Proactiv Skin Smoothing Exfoliator and La Roche-Posay Effaclar Duo Dual Action Acne Treatment. The full list and lot numbers was posted online Tuesday. “Even with daily use of these products for ...

Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise Research Campus in Allston that could employ hundreds. The Roche ...

Proactiv Skin Smoothing Exfoliator and La Roche-Posay Effaclar Duo Dual Action Acne Treatment. The full list and lot numbers was posted online Tuesday. The FDA stressed consumers face little risk ...

Ford has used some version of its famous script logo for more than a century, but despite its widespread usage, people are scratching their heads over a detail they just noticed. In a viral TikTok ...

ZURICH (Reuters) -Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in ...

Roivant, the source of Roche’s TL1A prospect, reported a 21% delta compared to placebo after 12 weeks. Prometheus Biosciences, which Merck acquired, saw a 31% placebo-adjusted rate of endoscopic ...